Concordance between HER‐2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients

[1]  H. Ashrafian,et al.  Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis. , 2014, Journal of the National Cancer Institute.

[2]  Sung-Bae Kim,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. , 2014, The Lancet. Oncology.

[3]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[4]  A. Ballestrero,et al.  Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions. , 2014, Gynecologic oncology.

[5]  L. Xerri,et al.  SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases , 2013, BMC Cancer.

[6]  F. Schmitt,et al.  Multinational study of oestrogen and progesterone receptor immunocytochemistry on breast carcinoma fine needle aspirates , 2013, Cytopathology : official journal of the British Society for Clinical Cytology.

[7]  M. Fernö,et al.  Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients , 2013, Cytopathology : official journal of the British Society for Clinical Cytology.

[8]  F. Calliada,et al.  Ultrasound guided fine-needle aspiration cytology of breast lesions. , 2011, Journal of ultrasound.

[9]  S. Bianchi,et al.  Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. , 2010, Gynecologic oncology.

[10]  M. Dowsett,et al.  Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. J. van de Vijver,et al.  Emerging technologies for assessing HER2 amplification. , 2009, American journal of clinical pathology.

[12]  F. André,et al.  Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer , 2009, Cancer.

[13]  G. Farshid,et al.  Assessment of 1183 screen-detected, category 3B, circumscribed masses by cytology and core biopsy with long-term follow up data , 2008, British Journal of Cancer.

[14]  J. Isola,et al.  Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Kaposi-Novák,et al.  Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR — A comparison with immunohistochemical and FISH results , 2006, Pathology & Oncology Research.

[16]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[17]  J. Nesland,et al.  Real-Time PCR Quantification of c-erbB-2 Gene is an Alternative for Fish in the Clinical Management of Breast Carcinoma Patients , 2004, International journal of surgical pathology.

[18]  D. Weaver,et al.  HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. , 2004, American journal of clinical pathology.

[19]  D. Weaver,et al.  HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. , 2004, American journal of clinical pathology.

[20]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[21]  Sarkis Meterissian,et al.  Psychological factors in clinical nutrition , 2002 .

[22]  Adam Bartlett,et al.  Improved Breast Cytology Results with Near Patient FNA Diagnosis , 2002, Acta Cytologica.

[23]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[24]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[25]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.